EMA Authorised: Fulvestrant Mylan (fulvestrant) — Mylan Pharmaceuticals Limited

View source ↗

Summary

The European Medicines Agency authorised Fulvestrant Mylan, a generic fulvestrant product, for the treatment of breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fulvestrant Mylan (fulvestrant)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms. MAH: Mylan Pharmaceuticals Limited. Decision date: 09/10/2025